Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
$29.1M
Market Cap • 11/18/20242017
(7 years)
2020
(4 years ago)
NASDAQ
Listing Exchange
Philadelphia
Headquarters • PennsylvaniaPremium
...and much more!